Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Curasight

3.69

 

DKK

 

+2.22 %

Less than 1K followers

CURAS

Spotlight Stock Market

Medical Equipment & Services

Health Care

Overview
Ownership
Investor consensus
Compare
+2.22%
+10.79%
-34.02%
-24.93%
-43.38%
-33.62%
-58%
-
-73.56%

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Read more
Market cap
165.63M DKK
Turnover
49.02K DKK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Coverage
Disclaimer
Claus Thestrup
Claus Thestrup

CEO, Sweden

Latest research

Latest analysis report

Released: 2025-05-07

Financial calendar
28/8
2025

Interim report Q2'25

27/11
2025

Interim report Q3'25

All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release5/28/2025, 3:25 PM

Curasight: Completed registration of rights issue

Curasight
Regulatory press release5/28/2025, 12:26 PM

Resolutions of the Annual General Meeting 2025 of Curasight A/S

Curasight
Regulatory press release5/21/2025, 6:14 AM

Curasight announces outcome in rights issue

Curasight

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/15/2025, 2:09 PM

Subscription of new shares in the Right Issue 2025 exercised by Curasight management

Curasight
Regulatory press release5/13/2025, 3:14 PM

Curasight: Notice of Annual General Meeting 2025

Curasight
Regulatory press release5/13/2025, 6:46 AM

Last day of the subscription period in Curasight's rights issue of shares

Curasight
Regulatory press release5/7/2025, 6:06 AM

Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer

Curasight
Curasight (One-pager): Funding of pipeline
Research5/7/2025, 6:02 AM by
Philip Coombes, Claus Thestrup

Curasight (One-pager): Funding of pipeline

Curasight (One-pager): Funding of pipeline

Curasight
Press release5/6/2025, 12:28 PM

BioStock: Teckningsperioden för Curasights företrädesemission har inletts

Curasight
Press release5/6/2025, 12:28 PM

BioStock: Curasight's rights issue subscription period has commenced

Curasight
Regulatory press release5/2/2025, 5:30 AM

Curasight: THE SUBSCRIPTION PERIOD IN CURASIGHT'S RIGHTS ISSUE OF SHARES BEGINS TODAY

Curasight
Regulatory press release4/30/2025, 10:17 AM

Curasight to present at HC Andersen Capital

Curasight
Regulatory press release4/29/2025, 8:22 PM

Curasight A/S publishes disclosure document regarding rights issue

Curasight
Press release4/29/2025, 7:12 AM

Redeye: Curasight Q1 - Securing runway to readouts

Curasight
Regulatory press release4/25/2025, 6:47 AM

Curasight: Annual Report for the fiscal year 2024

Curasight
Regulatory press release4/25/2025, 6:25 AM

Curasight: Interim report Q1 2025

Curasight
Regulatory press release4/24/2025, 6:30 AM

Curasight: CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE

Curasight
Regulatory press release4/23/2025, 9:38 AM

Resolutions of the Extraordinary General Meeting of Curasight A/S on 23 April 2025

Curasight
Press release4/11/2025, 6:26 AM

BioStock: Curasight stärker investerarbasen med Curium och Pentwater

Curasight
Press release4/11/2025, 6:26 AM

BioStock: Curasight strengthens the investor base with Curium and Pentwater

Curasight
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team